Study to Evaluate an Aflibercept (EYLEA®) Prefilled Syringe

Key Inclusion Criteria: * Participants who have neovascular age-related macular degeneration (AMD), diabetic macular edema (DME), retinal vein occlusion (RVO), or diabetic retinopathy (DR) with diabetic macular edema (DME) in the study eye Key Exclusion Criteria: * Evidence of active infectious blepharitis, keratitis, scleritis, or conjunctivitis in either eye * Any active intraocular inflammation or infection in either eye or history of intraocular inflammation or infection after past intravitreal injection treatment (IVT) injections with any agent in either eye * History of or any current indication of excessive bleeding and recurrent hemorrhages, including any prior excessive intraocular (including subconjunctival) bleeding or hemorrhages after IVT injection or intraocular procedures in either eye * Any intraocular surgery in the study eye at any time during the past 3 months * Current systemic infectious disease or a therapy for active infectious disease * Pregnant or breastfeeding women Note: Other inclusion/ exclusion apply